The Human Herpesvirus 8 (HHV-8) Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Human Herpesvirus 8 (HHV-8) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Human Herpesvirus 8 (HHV-8) Infections. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Human Herpesvirus 8 (HHV-8) Infections and features dormant and discontinued products.
GlobalData tracks two drugs in development for Human Herpesvirus 8 (HHV-8) Infections by two companies/universities/institutes. The top development phase for Human Herpesvirus 8 (HHV-8) Infections is preclinical with one drugs in that stage. The Human Herpesvirus 8 (HHV-8) Infections pipeline has two drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Human Herpesvirus 8 (HHV-8) Infections pipeline products market are: Microbiotix and AlloVir.
The key targets in the Human Herpesvirus 8 (HHV-8) Infections pipeline products market include Serine/Threonine Protein Kinase UL97 (HSRF3 Protein or Ganciclovir Kinase or UL97 or EC 2.7.11.), and DNA Polymerase (EC 2.7.7.7).
The key mechanisms of action in the Human Herpesvirus 8 (HHV-8) Infections pipeline product include DNA Polymerase (EC 2.7.7.7) Inhibitor with one drug in Phase I. The Human Herpesvirus 8 (HHV-8) Infections pipeline products include one routes of administration with the top ROA being Oral and two key molecule types in the Human Herpesvirus 8 (HHV-8) Infections pipeline products market including Cell Therapy, and Small Molecule.
Human Herpesvirus 8 (HHV-8) Infections overview
Human herpesvirus-8 (HHV-8), also known as Kaposi’s sarcoma-associated herpesvirus (KSHV), is a gamma herpesvirus that infects various cell types, including endothelial cells, lymphocytes, and dendritic cells. HHV-8 is the etiological agent of Kaposi’s sarcoma (KS), a vascular tumor that often affects immunocompromised individuals, such as those with AIDS or organ transplant recipients. HHV-8 is also associated with rare lymphoproliferative disorders such as primary effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD). The transmission of HHV-8 is not fully understood, but sexual contact, blood transfusion, and saliva exchange are possible routes. The prevalence of HHV-8 infection varies widely across different geographic regions and populations, ranging from 1% to 80%. Most HHV-8 infections are asymptomatic and latent, but reactivation can occur under conditions of immune suppression or inflammation. There is currently no vaccine or specific treatment for HHV-8 infection or its related diseases.
For a complete picture of Human Herpesvirus 8 (HHV-8) Infections’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
